文献速递炎症性肠病

乌司奴单抗维持治疗溃疡性结肠炎103例真实世界研究

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-07-23

基于GETAID队列的103例活动性溃疡性结肠炎患者,评估乌司奴单抗52周真实世界有效性与安全性;44%停药主要因无效,52周无激素临床缓解率32%,15例(16.9%)出现不良反应,4例严重。

要点

  • 52周时44%患者停用乌司奴单抗,主要因无效(41例)
  • 52周无激素临床缓解率为32%,其中71%直肠出血和排便频率亚评分为0
  • 15例(16.9%)出现不良反应,4例(4.5%)严重,包括1例心梗死亡

核心结论

  • 52周后超过半数难治性溃疡性结肠炎患者仍在接受乌司奴单抗治疗,约三分之一达到无激素临床缓解。

研究设计与样本

  • GETAID多中心队列研究,2019年1月至9月连续纳入103例活动性溃疡性结肠炎患者,第52周评估。

主要发现

  • 52周时45例(44%)停用乌司奴单抗,其中41例因无效停药。
  • 乌司奴单抗持续概率在3、6、9、12个月分别为96.1%、81.6%、71.7%、58.4%。
  • 52周总体无激素临床缓解率为32%,其中71%的患者直肠出血和排便频率亚评分为0。
  • 10例患者在中位6.7[4.3-10.6]个月内接受结肠切除术。
  • 15例(16.9%)出现不良反应,4例(4.5%)为严重不良反应,包括1例心肌梗死死亡。

关键数值与推荐

  • 缓解定义为部分Mayo临床评分≤2。
  • 纳入患者对免疫抑制剂、抗TNF药物和/或维得利珠单抗应答不足。

临床怎么用

  • 乌司奴单抗可作为难治性溃疡性结肠炎的维持治疗选择,但需关注约半数患者52周内停药及严重不良反应风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available. AIMS: To assess the real-world effectiveness and safety of ustekinumab in patients with UC. METHODS: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined as a partial Mayo Clinic score ≤2. RESULTS: We included 103 patients with UC (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) with an insufficient response to immunosuppressants, anti-TNFs and/or vedolizumab. At week 52, 45 (44%) patients had discontinued ustekinumab mainly due to lack of effectiveness (n = 41). The cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7% and 58.4% after 3, 6, 9 and 12 months respectively. The overall steroid-free clinical remission rate at week 52 was 32% of whom 71% had subscores of null for rectal bleeding and stool frequency. Ten patients underwent colectomy within a median of 6.7 [4.3-10.6] months. Adverse effects were observed in 15 (16.9%) patients; 4 (4.5%) were severe, including one patient who died from a myocardial infarction. CONCLUSION: After 52 weeks, over one-half of patients with refractory UC were still treated by ustekinumab and one-third were in steroid-free clinical remission.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021. PMID: 34296456. doi:10.1111/apt.16544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。